Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

Wells Fargo analyst Tianqi Hang has initiated coverage on Design Therapeutics (NASDAQ: DSGN) with an Overweight rating. The analyst has set a price target of $26 for the company's stock.